Drug Trial Radar · NCT04293679
Open Label, Dose Escalation Study for the Safety and Efficacy of STP705 in Adult Patients With isSCC
Last checked: Nov 19, 2026Latest source record: Jun 9, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
25
Actual
Start
Mar 21, 2019
Primary completion
Oct 21, 2020
Study completion Oct 21, 2020
Sponsor
- Lead sponsor
- SirnaomicsIndustry
- Sponsor type
- Industry
- Collaborators
- Amarex Clinical Research
- First posted
- Mar 3, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open label, dose escalation study to evaluate the safety and efficacy of intralesional injection of STP705 in adult patients with Cutaneous Squamous Cell Carcinoma in situ (isSCC, Bowen's disease). The purpose of this trial is to evaluate the safety, tolerability and efficacy of various doses of STP705 administered as Intralesional injection in subjects with isSCC. Goals: * To determine the safe and effective recommended dose of STP705 for the treatment of isSCC. * Analysis of biomarkers common to isSCC formation pathway including TGF-β1 and COX-2.
Conditions
- Bowen's Disease
- Cutaneous Squamous Cell Carcinoma in Situ
Interventions
STP705Drug
Investigational Product
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of participants with histological clearance of treated isSCC lesion at the End of Treatment (EOT).Time frame: 6 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Center for Clinical and Cosmetic Research
Aventura, Florida
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.